Sensitivity and Reproducibility of 18F-fluorodeoxyglucose Positron Emission Tomography for Assessment of Respiratory Muscle Activity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-05

Study Completion Date

2023-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The assessment of respiratory muscle function is critical within both clinical and research settings. Tools for the assessment of respiratory muscle function are especially useful in diagnosing, phenotyping, understanding pathophysiology, and assessing treatment responses in patients with respiratory symptoms, including critically hill patients and patients with respiratory and/or neuromuscular diseases. Respiratory muscle function is most commonly assessed using flow (i.e. spirometry) and pressure measurements during spontaneous ventilation, voluntary respiratory efforts, or artificially evoked responses using magnetic or electrical stimulation. Some of these approaches may be limited within patients suffering from neuromuscular diseases. The study hypothesis is the 18F-FDG PET technology, heavily used for clinical oncology purposes (diagnostic, staging, response to treatment, prognosis), could be an interesting alternative to invasive measurement of the respiratory muscle activity. In addition, it may contribute to further validate metrics based on multiparametric ultrasound imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Regional Distribution of Ventilation to Assess Respiratory Muscle Dysfunction

NCT01569217

Respiratory Failure Neuromuscular Disorder Diaphragmatic Paralysis

UNKNOWN

Respiratory Muscle Strength in Patients With Obesity Hypoventilation Syndrome (OHS) or With a Precursor of the Disease

NCT03854058

Obesity Hypoventilation Syndrome

RECRUITING

Ultrasound Assessment of the Thickening Fraction of the Respiratory Muscles for Predicting Weaning Outcomes

NCT06724302

Weaning From Mechanical Ventilation

NOT_YET_RECRUITING

Inspiratory Muscle Training Effectiveness in Sympathetic Activity and Functional Capacity in Patients With Heart Failure

NCT02600000

Heart Failure

UNKNOWN NA

Evaluation of Skeletal Muscle Function Using Ultrasonic Elastography

NCT05805332

Chronic Obstructive Pulmonary Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The assessment of respiratory muscle function is critical within both clinical and research settings. Tools for the assessment of respiratory muscle function are especially useful in diagnosing, phenotyping, understanding pathophysiology, and assessing treatment responses in patients with respiratory symptoms, including critically hill patients and patients with respiratory and/or neuromuscular diseases. Respiratory muscle function is most commonly assessed using flow (i.e. spirometry) and pressure measurements during spontaneous ventilation, voluntary respiratory efforts, or artificially evoked responses using magnetic or electrical stimulation. Some of these approaches may be limited, for instance, when facial muscle weakness occurs and/or when glottis function is compromised, for example in patients with bulbar amyotrophic lateral sclerosis or myopathies. Consequently, widely used respiratory measures can be poor predictors of respiratory muscle alterations and this may contribute to affect clinical decisions such as the time when non-invasive ventilation should be initiated within the disease continuum.

Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement of positron emission from radiolabeled tracer molecules. These radiotracers allow biologic processes to be measured and whole-body images to be obtained which demonstrates sites of radiotracer accumulation. Fluorodeoxyglucose (18F-FDG) is a radiolabeled glucose molecule and is the most common radiotracer used in clinical practice. 18F-FDG PET is most frequently coupled with computed tomography but may also be coupled with magnetic resonance imaging (18F-FDG PET-MRI). 18F-FDG PET is heavily used for clinical oncology purposes (diagnostic, staging, response to treatment, prognosis). 18F-FDG PET also finds applications in other fields for detecting infections and inflammatory processes. 18F-FDG may also be used in muscles that are major user of glucose. 18F-FDG PET offers the opportunity to assess the patterns and work amount of multiple muscles simultaneously, providing a global view of the muscles involved in the realization of a motor task, as previously demonstrated in shoulder muscles.

Ultrasound imaging (US) is attracting a growing interest for the assessment of respiratory muscle function, as it allows bedside and non-invasive assessments. Recently, new US techniques such as shear wave elastography (SWE) have shown promises for the assessment of respiratory muscle work. However, the ability of variables derived from respiratory muscle US to reflect increased muscle work remains unclear. Hence, building evidences supporting non-invasive US biomarkers for respiratory muscle function is necessary.

18F-FDG PET offers a unique opportunity to investigate patterns and work amount of the respiratory muscles. In a resting state, 18F-FDG uptake in the respiratory muscle is known to be small. However, and to the best of our knowledge, 18F-FDG uptake of the respiratory muscles at rest in healthy subjects has never been specifically reported. It is unclear whether 18F-FDG PET may be used to monitor changes in respiratory muscle activity within the disease continuum or in response to an intervention such as the initiation of non-invasive ventilation. The reproducibility of increase 18F-FDG uptake of the respiratory muscles induced remains to be assessed and is a prerequisite to determine its sensitivity to change. Moreover, the relationship between increase 18F-FDG uptake and respiratory muscle work as assessed using other methods (e.g. flow and pressure measurements, surface electromyography (sEMG)) and variables derived from multiparametric US remains to be determined. Since MRI does not use ionizing radiations, and because of very higher soft-tissue contrast capabilities, combining PET to MRI instead of CT is of better relevance for our PET muscular analyses purpose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Muscle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control subjects

Visit 1 (V1) (Duration: 2.5h)

* Information, verification of inclusion and exclusion criteria, information note.
* Consent form.
* Location of the diaphragm and parasternal intercostal muscle using ultrasound.
* Measurements at rest (mouth pressures, sEMG, ultrasound imaging).
* Injection of 3 MBq/kg of 18F-FDG.
* 1h resting period.
* 18F-FDG PET-MRI scan.

Visit 2 (V2) 3-10 days after V1 (Duration: 3h)

* Location of the diaphragm and parasternal intercostal muscle.
* Measurements at rest (mouth pressures, sEMG, ultrasound imaging)
* Magnetic stimulation of the phrenic nerves
* Ventilation against inspiratory loading
* Magnetic stimulation of the phrenic nerves
* Injection of 3 MBq/kg of 18F-FDG
* 1h resting period
* 18F-FDG PET-MRI scan

Visit 3 (V3) 3-10 days after V2 (Duration: 3h)

\- Identical to visit 2

Group Type EXPERIMENTAL